Exforge hct (amlodipine besylate; hydrochlorothiazide; valsartan) drug profile, 2024?

Question

Accepted Answer

Exforge HCT (amlodipine besylate + hydrochlorothiazide + valsartan)
Drug profile – 2024 edition

1. Product Overview

Component	Dose per tablet	Class	Typical pharmacologic role
Amlodipine besylate	5 mg or 10 mg	L-type calcium‑channel blocker	Vasodilation → ↓ peripheral resistance
Hydrochlorothiazide (HCT)	12.5 mg or 25 mg	Thiazide diuretic	↓ plasma volume → ↓ preload
Valsartan	80 mg or 160 mg	Angiotensin‑II type 1 (AT₁) receptor blocker (ARB)	↓ vasoconstriction & aldosterone release

Exforge HCT is a fixed‑dose combination tablet taken once daily (preferably in the morning). The 5 mg/12.5 mg/80 mg (Aml/HCT/Val) and 10 mg/25 mg/160 mg formulations are the only FDA‑approved strengths. The drug is sold under the brand name Exforge HCT (and generic equivalents). It is indicated for the treatment of essential (primary) hypertension in adults when monotherapy is insufficient.

2. Pharmacology & Mechanism of Action

Component	Key PK/PD	Mechanistic Notes
Amlodipine	• Absorbed >95 %	• Blocks L‑type Ca²⁺ channels in vascular smooth muscle → vasodilation, ↓ SVR.
	• Half‑life ≈ 30–50 h	• Oral bioavailability 60‑70 %
	• Metabolized mainly by CYP3A4
Hydrochlorothiazide	• Rapid absorption (Tmax ≈ 2 h)	• Inhibits Na⁺/Cl⁻ cotransporter in distal tubule → natriuresis, ↓ ECF volume.
	• Half‑life ≈ 6–10 h	• Potassium‑losing diuretic.
Valsartan	• Rapid absorption (Tmax ≈ 0.5–1 h)	• Competitive antagonist of AT₁ receptors → vasodilation, ↓ aldosterone.
	• Half‑life ≈ 5–6 h	• Metabolized by CYP2C9, CYP3A4 (minor).

Synergy – The three agents target distinct segments of the cardiovascular system: amlodipine reduces afterload, HCT reduces preload, and valsartan blocks the renin–angiotensin–aldosterone system (RAAS). The combination achieves superior BP control with fewer doses, improving adherence.

3. Indications

Essential hypertension in adults (≥ 18 yr) when monotherapy fails to achieve target BP (usually < 140/90 mm Hg or < 130/80 mm Hg for high‑risk patients).
It can be used as add‑on therapy to other antihypertensives if additional BP reduction is needed.

Note: Exforge HCT is not indicated for hypertensive emergencies or for treatment of hypertension secondary to secondary causes (e.g., renal artery stenosis, pheochromocytoma).

4. Dosage & Administration

Age	Weight	Starting Dose	Titration	Max Dose	Special notes
Adult	≥ 65 kg	5 mg / 12.5 mg / 80 mg once daily	Increase by 1 tablet (i.e., +5 mg / 25 mg / 160 mg) every 2–4 weeks to max 10 mg / 25 mg / 160 mg	10 mg / 25 mg / 160 mg	• Initiate on low dose in patients > 70 yr or with CKD.
Pediatric (≥ 12 yr)	< 65 kg	Not FDA‑approved	–	–	–

Take with or without food – food only affects amlodipine absorption slightly.
Avoid alcohol – increases risk of orthostatic hypotension & edema.
Monitor BP and electrolytes (especially K⁺) at baseline, 1–2 weeks, and 4–6 weeks after dose change.

5. Contraindications

History of hypersensitivity to any component (e.g., amlodipine, HCT, valsartan).
Hyperkalemia (serum K⁺ > 5.5 mEq/L) – valsartan can increase K⁺, HCT decreases it; net effect may be unpredictable.
Severe renal impairment (CrCl < 30 mL/min) or on dialysis – valsartan is renally excreted; HCT is contraindicated in CrCl < 25 mL/min.
Severe hepatic impairment – valsartan clearance ↓.
Pregnancy (any trimester) – valsartan is category X; amlodipine & HCT are category C.
Breastfeeding – valsartan is excreted into milk; avoid while nursing.
Angioedema related to ACE inhibitors or ARBs.

6. Warnings & Precautions

Issue	Practical Points
Hypotension/Orthostatic dizziness	Initiate low dose, monitor BP, educate patient.
Electrolyte disturbances	Monitor K⁺, Na⁺; consider potassium supplements if hypokalemia, or potassium‑sparing diuretic if hyperkalemia.
Renal function	Baseline & periodic serum creatinine, BUN, eGFR.
Heart failure	ARBs (valsartan) reduce mortality in HF, but in decompensated HF they can worsen renal function. Use cautiously.
Liver disease	Monitor liver enzymes; valsartan metabolism ↓.
Fluid & weight gain	Edema may occur; counsel on sodium restriction.
Pregnancy & lactation	Contraindicated; switch to alternative antihypertensives.
Alcohol

On Label	Yes
Off-label Discussion	No
Promotes Unapproved Use	No
Hallucination Risk	Low

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Exforge hct (amlodipine besylate; hydrochlorothiazide; valsartan) drug profile, 2024?

1. Product Overview

2. Pharmacology & Mechanism of Action

3. Indications

4. Dosage & Administration

5. Contraindications

6. Warnings & Precautions

AI-Drug Label Prescribing Information Alignment Report

Grade A

Excellent

Mostly Aligned

Summary

Category Scores

Accurate Statements

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Regulatory Assessment

Recommendation

Mostly Aligned

Drug Brand Mention Assessment

Best Known For

Core Claims

Differentiators